GB9401182D0 - Antibodies to EGF receptor and their antitumour effect - Google Patents

Antibodies to EGF receptor and their antitumour effect

Info

Publication number
GB9401182D0
GB9401182D0 GB9401182A GB9401182A GB9401182D0 GB 9401182 D0 GB9401182 D0 GB 9401182D0 GB 9401182 A GB9401182 A GB 9401182A GB 9401182 A GB9401182 A GB 9401182A GB 9401182 D0 GB9401182 D0 GB 9401182D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
egf receptor
antitumour effect
antitumour
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9401182A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INST OF CANCER RESEARCH
Institute of Cancer Research
Original Assignee
INST OF CANCER THE RESEARCH
Institute of Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INST OF CANCER THE RESEARCH, Institute of Cancer Research filed Critical INST OF CANCER THE RESEARCH
Priority to GB9401182A priority Critical patent/GB9401182D0/en
Publication of GB9401182D0 publication Critical patent/GB9401182D0/en
Application status is Pending legal-status Critical

Links

GB9401182A 1994-01-21 1994-01-21 Antibodies to EGF receptor and their antitumour effect Pending GB9401182D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9401182A GB9401182D0 (en) 1994-01-21 1994-01-21 Antibodies to EGF receptor and their antitumour effect

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9401182A GB9401182D0 (en) 1994-01-21 1994-01-21 Antibodies to EGF receptor and their antitumour effect
AU14601/95A AU691865B2 (en) 1994-01-21 1995-01-23 Antibodies to egf receptor and their antitumour effect
CA 2180834 CA2180834A1 (en) 1994-01-21 1995-01-23 Antibodies to egf receptor and their antitumour effect
EP19950906400 EP0737251A1 (en) 1994-01-21 1995-01-23 Antibodies to egf receptor and their antitumour effect
JP51942195A JPH09510605A (en) 1994-01-21 1995-01-23 Antibodies to Egf receptor and its anti-tumor effects
PCT/GB1995/000118 WO1995020045A1 (en) 1994-01-21 1995-01-23 Antibodies to egf receptor and their antitumour effect

Publications (1)

Publication Number Publication Date
GB9401182D0 true GB9401182D0 (en) 1994-03-16

Family

ID=10749157

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9401182A Pending GB9401182D0 (en) 1994-01-21 1994-01-21 Antibodies to EGF receptor and their antitumour effect

Country Status (6)

Country Link
EP (1) EP0737251A1 (en)
JP (1) JPH09510605A (en)
AU (1) AU691865B2 (en)
CA (1) CA2180834A1 (en)
GB (1) GB9401182D0 (en)
WO (1) WO1995020045A1 (en)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2191702T3 (en) * 1994-03-17 2003-09-16 Merck Patent Gmbh Single chain Fv anti-EGFR and anti-EGFR antibodies.
CU22545A1 (en) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtaining a chimeric and humanized antibody against the epidermal growth factor receptor for diagnostic and therapeutic use
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
NZ516633A (en) 1999-06-21 2004-09-24 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE60234094D1 (en) 2001-05-11 2009-12-03 Ludwig Inst For Cancer Res Ltd Specific binding proteins and their use
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
KR100945108B1 (en) 2001-06-13 2010-03-02 젠맵 에이/에스 Human Monoclonal Antibodies to Epidermal Growth Factor Receptor EGFR
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2499816C (en) 2002-09-27 2013-07-30 Xencor, Inc. Optimized fc variants and methods for their generation
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10349113A1 (en) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma A process for preparing Aminocrotonylverbindungen
EP1701979A2 (en) * 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
EP1697741A4 (en) 2003-12-04 2008-02-13 Xencor Inc Methods of generating variant proteins with increased host string content and compositions thereof
SI2471813T1 (en) 2004-07-15 2015-03-31 Xencor, Inc. Optimized Fc variants
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
KR101027427B1 (en) 2004-11-12 2011-04-11 젠코어 인코포레이티드 Fc VARIANTS WITH INCREASED BINDING TO FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PE07772006A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Indolinone derivatives for the treatment or prevention of fibrotic diseases
CA2596835C (en) 2005-02-07 2019-08-20 Glycart Biotechnology Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
CN101370525B (en) 2005-08-19 2013-09-18 Abbvie 公司 Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500354A3 (en) 2005-08-19 2012-10-24 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
AR062223A1 (en) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Adhesion molecules to the antigen that attach to EGFR, vectors encoding, and uses of these
MX2009002710A (en) 2006-09-18 2009-03-25 Boehringer Ingelheim Int Method for treating cancer harboring egfr mutations.
NZ578943A (en) 2007-03-01 2012-09-28 Symphogen As Recombinant anti-epidermal growth factor receptor antibody compositions
CN101910199B (en) 2007-12-26 2015-11-25 Xencor公司 Altered binding to FcRn Fc variants
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2009149185A2 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
MX2010014574A (en) 2008-07-08 2011-04-27 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof.
RU2540146C2 (en) 2008-08-29 2015-02-10 Симфоген А/С Compositions of recombinant antibodies from epidermal growth factor receptor
TWI572357B (en) 2008-10-14 2017-03-01 Genentech Inc Immunoglobulin variants and uses thereof
US8835610B2 (en) 2009-03-05 2014-09-16 Abbvie Inc. IL-17 binding proteins
EP2451445B1 (en) 2009-07-06 2019-04-03 Boehringer Ingelheim International GmbH Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
PE15302012A1 (en) 2009-09-01 2012-12-22 Abbvie Inc Immunoglobulins Dual variable domain
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche highly concentrated anti-CD20 antibody of pharmaceutical formulations. Use of the formulation. treatment method.
UY32948A (en) 2009-10-15 2011-02-28 Abbott Lab Immunoglobulins Dual variable domain and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab Immunoglobulins Dual variable domain and uses thereof
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
JP2013523098A (en) 2010-03-29 2013-06-17 ザイムワークス,インコーポレイテッド Antibody with enhanced or suppressed effector function
KR101539684B1 (en) 2010-05-14 2015-07-27 애브비 인코포레이티드 Il-1 binding proteins
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab Immunoglobulins Dual variable domain and uses thereof
CN103052649B (en) 2010-07-29 2015-12-16 Xencor公司 Antibodies having a modified isoelectric point
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012027570A2 (en) 2010-08-26 2012-03-01 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
BR112013015944A2 (en) 2010-12-21 2018-06-19 Abbvie Inc Bispecific double-domain alpha and beta variable domain immunoglobulins and their uses.
AU2012258637B2 (en) 2011-05-24 2017-07-20 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2019071023A1 (en) 2017-10-04 2019-04-11 Yale University Compositions and methods for making selenocysteine containing polypeptides
WO2013009868A1 (en) 2011-07-11 2013-01-17 Yale University Compositions and methods for making selenocysteine containing polypeptides
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
JP6310394B2 (en) 2011-10-10 2018-04-11 ゼンコア インコーポレイテッド Methods for purifying antibodies
WO2013063095A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
AU2012362326A1 (en) 2011-12-30 2014-07-24 Abbvie Inc. Dual variable domain immunoglobulins against IL-13 and/or IL-17
SG11201408161RA (en) 2012-06-08 2015-01-29 Sutro Biopharma Inc Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
TW201402608A (en) 2012-07-12 2014-01-16 Abbvie Inc IL-1 binding proteins
CN104981254B (en) 2012-08-31 2018-05-22 苏特罗生物制药公司 Comprising a modified amino acid of the azido
CN105431453A (en) 2012-11-01 2016-03-23 艾伯维公司 Stable dual variable domain immunoglobulin protein formulations
US9163093B2 (en) 2012-11-01 2015-10-20 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US20140377253A1 (en) 2013-03-15 2014-12-25 Abbvie Biotherapeutics Inc. Fc variants
BR112015023797A2 (en) 2013-03-15 2017-10-24 Abbvie Inc dual specificity binding proteins directed against il-1b and / or il-17
CN105451767A (en) 2013-03-15 2016-03-30 泽恩格尼亚股份有限公司 Multivalent and monovalent multispecific complexes and their uses
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
EP3336103A1 (en) 2013-07-10 2018-06-20 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
KR20160055253A (en) 2013-09-12 2016-05-17 할로자임, 아이엔씨 Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
EP3055298A1 (en) 2013-10-11 2016-08-17 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015057906A1 (en) * 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CA2943621A1 (en) 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
JP2017537069A (en) 2014-10-23 2017-12-14 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. Treatment of cancer with anti-NKG2A agent
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
PE13242017A1 (en) 2014-11-26 2017-09-11 Xencor Inc heterodimeric antibodies that bind to tumor antigens CD3 and
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
TW201710286A (en) 2015-06-15 2017-03-16 Abbvie Inc Anti vegf, pdgf and / or receptor binding proteins
EP3387013A1 (en) 2015-12-07 2018-10-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
JP2019518712A (en) 2016-03-14 2019-07-04 ウニヴァーシテテット イ オスロ Modified immunoglobulin with altered FcRn
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
EP3472197A1 (en) 2016-06-15 2019-04-24 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
KR20190020341A (en) 2016-06-28 2019-02-28 젠코어 인코포레이티드 Heterodimer dimer antibody that binds to somatostatin receptor 2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
KR100240308B1 (en) * 1991-03-06 2000-01-15 플레믹 크리스티안 Humanized and chimeric monoclonal antibodies

Also Published As

Publication number Publication date
AU691865B2 (en) 1998-05-28
JPH09510605A (en) 1997-10-28
EP0737251A1 (en) 1996-10-16
CA2180834A1 (en) 1995-07-27
WO1995020045A1 (en) 1995-07-27
AU1460195A (en) 1995-08-08

Similar Documents

Publication Publication Date Title
GB2292533B (en) Improved sifting screen
GB2334957B (en) Monovalent antibody fragments
KR100271382B1 (en) Human receptor h4-1bb
GB2240120B (en) Block for paving and like uses
ZA9605857B (en) Cable-sheathing composition
GB9608873D0 (en) Absorbent article
TW392501U (en) Absorbent article
IL101690D0 (en) Antibodies and methods utilizing the same
IL123332D0 (en) VEGF-related protein
HU0001547A3 (en) Novel form of s-omeprazole
IL136335D0 (en) Monoclonal human natural antibodies
TW381470U (en) Absorbent article
PT837927E (en) Anti-cd80 antibodies
GB9115364D0 (en) Antibody
GB9125979D0 (en) Antibody
GB9109645D0 (en) Recombinant antibodies
ZA9508642B (en) Novel carboxylicatives their preparation and use
IL116325D0 (en) Substituted 1h-imidazoles their preparation and use
GB9610955D0 (en) Sizing composition
ZA9709185B (en) Anti-ErbB2 antibodies
PL189696B1 (en) Modified/chimeric superantigenes and their application
IL122944D0 (en) Halogenobenzimidazoles and their preparation
GB9610992D0 (en) Concentrated antibody preparation
HU9603525D0 (en) Vironectin receptor antagonists
GB9500089D0 (en) Thixotropic materials